Latanoprostene Bunod: uses, dosing, side effects & brands
Latanoprostene Bunod is a medicine sold in the U.S. under 2 brand and generic names. Below: what the FDA label says, every product that contains it, what the pills look like, and its recall record.
Key facts
- Available as
- Drops
- Sold as
- 2 products — Latanoprostene Bunod and Vyzulta
- Prescription?
- Prescription only
- Generic available?
- Yes
How latanoprostene bunod is dosed
From the FDA label for Latanoprostene Bunod (application ANDA217387). Other latanoprostene bunod products — different forms, different strengths — are dosed differently. Follow the label for the one you were prescribed.
The recommended dosage is one drop in the conjunctival sac of the affected eye(s) once daily in the evening. Do not administer latanoprostene bunod ophthalmic solution, 0.024% more than once daily since it has been shown that more frequent administration of prostaglandin analogs may lessen the intraocular pressure lowering effect. If latanoprostene bunod ophthalmic solution is to be used concomitantly with other topical ophthalmic drug products to lower intraocular pressure, administer each drug product at least five (5) minutes apart. One drop in the affected eye(s) once daily in the evening.
Latanoprostene Bunod side effects
The following adverse reactions are described elsewhere in the labeling: • Pigmentation [ see Warnings and Precautions (5.1) ] • Eyelash Changes [ see Warnings and Precautions (5.2) ] • Intraocular Inflammation [ see Warnings and Precautions (5.3) ] • Macular Edema [ see Warnings and Precautions (5.4) ] • Bacterial Keratitis [ see Warnings and Precautions (5.5) ] • Use with Contact Lens [ see Warnings and Precautions (5.6 )] Most common ocular adverse reactions with incidence ≥ 2% are conjunctival hyperemia (6%), eye irritation (4%), eye pain (3%), and instillation site pain (2%). ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Gland Pharma at (609) 250-7990 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Latanoprostene bunod ophthalmic solution was evaluated in 811 patients in 2 controlled clinical trials of up to 12 months duration. The most common ocular adverse reactions observed in patients treated with latanoprostene bunod were: conjunctival hyperemia (6%), eye irritation (4%), eye pain (3%), and instillation site pain (2%). Approximately 0.6% of patients discontinued…
Who shouldn’t take latanoprostene bunod
None. None.
Every latanoprostene bunod product we track (2)
Same active ingredient — different manufacturer, form, price and FDA recall record. That last one is what our independent score measures.
| # | Drug | Rating | Type | Form | Generic? | Pharmacy pays | |
|---|---|---|---|---|---|---|---|
| 1 | Not yet rated | Prescription | Drops | No data | — | View → | |
| 2 | Not yet rated | Prescription | Drops | No data | — | View → |
Latanoprostene Bunod and breastfeeding
From LactMed, the US National Library of Medicine’s Drugs and Lactation Database — quoted, not rewritten.
Full LactMed record for latanoprostene bunod: levels in milk, effects in breastfed infants, and the drugs it would consider insteadNo information is available on the use of latanoprostene bunod during breastfeeding. Because of the extremely low levels in plasma after application to the eye and short half-life, it is not likely to reach the breastmilk or bloodstream of the infant or to cause any adverse effects in breastfed infants. Professional guidelines consider prostaglandin eye drops acceptable during breastfeeding. To further diminish the amount of drug that reaches the breastmilk after using eye drops, place pressure over the tear duct by the corner of the eye for 1 minute or more, then remove the excess solution with an absorbent tissue.
National Institute of Child Health and Human Development, record revised February 15, 2025. LactMed states its information is not a substitute for professional judgement.
What people report to the FDA about latanoprostene bunod
The FDA Adverse Event Reporting System (FAERS) collects reports from patients and clinicians. It holds 59 reports naming latanoprostene bunod, and the FDA flagged 75% of those reports as serious. The effects reported most often — leaving out reports about overdose, misuse or the condition being treated, which dominate the raw list for common medicines:
- hypoglycaemia18 reports
- urinary incontinence9 reports
- loss of consciousness6 reports
- visual field defect5 reports
- abdominal discomfort4 reports
- arthralgia4 reports
- blood immunoglobulin g increased4 reports
- blood urine present4 reports
Read these as a signal, not a rate. A report does not mean latanoprostene bunod caused the effect — anyone can file one, and many describe people taking several medicines for several conditions. Crucially there is no denominator: FAERS does not record how many people took the drug, so these counts cannot be turned into “X% of patients” — a bigger number often just means a more widely used or more talked-about drug. Duplicates exist, and publicity drives reporting. For what is actually established, read the FDA label section above.
Source: openFDA drug/event (FAERS), retrieved July 25, 2026.
Related calculators
Frequently asked questions
What is latanoprostene bunod?
Latanoprostene bunod ophthalmic solution, 0.024% is a prostaglandin analog formulated as a sterile topical ophthalmic solution. Latanoprostene bunod ophthalmic solution contains the active ingredient latanoprostene bunod 0.24 mg/mL, the preservative benzalkonium chloride 0.2 mg/mL, and the following inactive ingredients: polysorbate 80, glycerin, EDTA, and water. The formulation is buffered to pH 5.5 with citric acid/sodium citrate.
Can you take latanoprostene bunod with other medicines?
It depends on the medicine. We check it against the FDA labels rather than guessing: our interaction checker searches each drug's own label for the other and quotes what it says, naming the section it came from. Run latanoprostene bunod against whatever else you take — and remember that a label not naming a drug is not the same as that combination being safe.
What brand names is latanoprostene bunod sold under?
We track 2 latanoprostene bunod-containing products in the U.S.: Latanoprostene Bunod and Vyzulta. They are the same active ingredient; they differ in form, manufacturer, price and FDA recall record.
What forms does latanoprostene bunod come in?
Across the brands we track, latanoprostene bunod is currently marketed as drops, per the FDA's National Drug Code Directory. Each form is dosed differently — follow the label for the exact product you were prescribed.
Is there a generic latanoprostene bunod?
Yes. Our catalog lists 1 generic latanoprostene bunod product alongside the brand versions. A generic has the same active ingredient and must meet the FDA's bioequivalence standard; it usually costs less. Ask your pharmacist which one your plan covers.
Cite this page
- APA
- pharmaranks. (2026, July 24). Latanoprostene Bunod: uses, dosing, side effects & brands. https://pharmaranks.com/drugs/latanoprostene-bunod
- MLA
- “Latanoprostene Bunod: uses, dosing, side effects & brands.” pharmaranks, 24 July 2026, https://pharmaranks.com/drugs/latanoprostene-bunod.
We summarise public FDA and NIH sources — for a clinical claim, cite the primary source we link to as well.
Sources: FDA openFDA drug label, National Drug Code Directory, and Enforcement (recall) database. This page reproduces public FDA data and is not medical advice. Dosing is set by your prescriber.
Read the full FDA label for latanoprostene bunod on DailyMed (NIH) ↗.